An Open-Label, Single-Sequence, Crossover Study to Investigate the Interaction of Multiple Doses of BMS-986322 at Steady State and Multiple Doses of a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Participants
Latest Information Update: 22 Aug 2023
At a glance
- Drugs BMS 986322 (Primary) ; Ethinylestradiol/norethisterone
- Indications Psoriasis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 15 Aug 2023 Status changed from not yet recruiting to completed.
- 17 Oct 2022 New trial record